Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.50 |
| ▸ | SLC2A3 | P11169 | 2/20 | 0.50 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386438 | 0.88 | GPR119 (0.70) | GPR119CYP2C9KCNH2HPGDS | |
| SCHEMBL1071139 | 0.85 | GPR119 (0.62) | GPR119CYP2C9KCNH2SMN1; SMN2MAPT | |
| SCHEMBL5133409 | 0.83 | SLC2A1 (0.49) | GPR119SLC2A1SLC2A3SLC2A2SMN1; SMN2 | |
| SCHEMBL1071250 | 0.82 | GPR119 (0.61) | GPR119CYP2C9KCNH2SMN1; SMN2KDM4E | |
| SCHEMBL288589 | 0.79 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390951 | 0.79 | GPR119 (0.68) | GPR119CYP2C9KCNH2SMN1; SMN2ALDH1A1 | |
| SCHEMBL1904029 | 0.79 | GPR119 (0.51) | GPR119CYP2C9KCNH2SMN1; SMN2KDM4E | |
| SCHEMBL5208216 | 0.77 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL27747902 | 0.76 | GPR119 (0.62) | GPR119CYP2C9KCNH2SMN1; SMN2MAPT | |
| SCHEMBL1252736 | 0.74 | GPR119 (0.70) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287165-A2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7625906-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | GPR119 36/4885SLC2A1 235/4885SLC2A3 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.